PGS Preprint: PGP000238

Publication Information (EuropePMC)
Title Understanding genetic risk factors for common side effects of antidepressant medications
doi 10.1101/2021.07.12.21260397
Publication Date July 16, 2021
Journal medRxiv Preprint
Author(s) Campos AI, Mulcahy A, Thorp JG, Wray NR, Byrne EM, Lind PA, Medland SE, Martin NG, Hickie IB, Rentería ME.
Released in PGS Catalog: Oct. 7, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000909
(PRS_Headaches)
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Headache Headache 2,862,172
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000909/ScoringFiles/PGS000909.txt.gz
PGS000910
(PRS_BMI)
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Body mass index body mass index 735,440
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000910/ScoringFiles/PGS000910.txt.gz
PGS000907
(PRS_MDD)
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Major depressive disorder major depressive disorder 1,773,528
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000907/ScoringFiles/PGS000907.txt.gz
PGS000908
(PRS_Insomnia)
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Insomnia insomnia 2,746,982
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000908/ScoringFiles/PGS000908.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002681 PGS000907
(PRS_MDD)
PSS001279|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Escitalopram takers OR: 1.0 [0.92, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002682 PGS000907
(PRS_MDD)
PSS001284|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Venlafaxine takers OR: 1.05 [0.96, 1.15] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002684 PGS000907
(PRS_MDD)
PSS001281|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Mirtazapine takers OR: 1.05 [0.91, 1.22] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002685 PGS000907
(PRS_MDD)
PSS001277|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Desvenlafaxine takers OR: 1.01 [0.91, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002686 PGS000907
(PRS_MDD)
PSS001276|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Citalopram takers OR: 1.02 [0.9, 1.16] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002687 PGS000907
(PRS_MDD)
PSS001280|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Fluoxetine takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002688 PGS000907
(PRS_MDD)
PSS001278|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Duloxetine takers OR: 1.06 [0.95, 1.2] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002689 PGS000907
(PRS_MDD)
PSS001282|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Paroxetine takers OR: 1.08 [0.92, 1.26] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002690 PGS000907
(PRS_MDD)
PSS001243|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Sertraline takers OR: 1.06 [0.98, 1.14] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002691 PGS000907
(PRS_MDD)
PSS001239|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Escitalopram takers OR: 1.06 [0.98, 1.15] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002692 PGS000907
(PRS_MDD)
PSS001244|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Venlafaxine takers OR: 1.01 [0.93, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002693 PGS000907
(PRS_MDD)
PSS001235|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Amitriptyline takers OR: 0.96 [0.83, 1.1] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002694 PGS000907
(PRS_MDD)
PSS001241|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Mirtazapine takers OR: 1.07 [0.93, 1.23] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002695 PGS000907
(PRS_MDD)
PSS001237|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Desvenlafaxine takers OR: 0.97 [0.87, 1.07] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002696 PGS000907
(PRS_MDD)
PSS001236|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Citalopram takers OR: 0.99 [0.87, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002697 PGS000907
(PRS_MDD)
PSS001240|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Fluoxetine takers OR: 1.16 [1.04, 1.29] Variance explained (Nagelkerke's R2*100): 0.41 sex, age at study enrollment, genetic PCs 1-20
PPM002698 PGS000907
(PRS_MDD)
PSS001238|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Duloxetine takers OR: 0.98 [0.88, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002699 PGS000907
(PRS_MDD)
PSS001242|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Paroxetine takers OR: 1.08 [0.93, 1.24] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002700 PGS000907
(PRS_MDD)
PSS001373|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Sertraline takers OR: 1.03 [0.94, 1.12] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002701 PGS000907
(PRS_MDD)
PSS001369|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Escitalopram takers OR: 1.01 [0.9, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002702 PGS000907
(PRS_MDD)
PSS001374|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Venlafaxine takers OR: 1.1 [1.0, 1.22] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002703 PGS000907
(PRS_MDD)
PSS001365|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Amitriptyline takers OR: 0.99 [0.81, 1.2] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002704 PGS000907
(PRS_MDD)
PSS001371|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Mirtazapine takers OR: 1.03 [0.86, 1.24] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002705 PGS000907
(PRS_MDD)
PSS001367|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Desvenlafaxine takers OR: 1.04 [0.92, 1.18] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002707 PGS000907
(PRS_MDD)
PSS001370|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Fluoxetine takers OR: 1.06 [0.95, 1.19] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002708 PGS000907
(PRS_MDD)
PSS001368|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Duloxetine takers OR: 0.9 [0.79, 1.04] Variance explained (Nagelkerke's R2*100): 0.21 sex, age at study enrollment, genetic PCs 1-20
PPM002709 PGS000907
(PRS_MDD)
PSS001372|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Paroxetine takers OR: 1.19 [1.0, 1.41] Variance explained (Nagelkerke's R2*100): 0.53 sex, age at study enrollment, genetic PCs 1-20
PPM002710 PGS000907
(PRS_MDD)
PSS001303|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Sertraline takers OR: 1.13 [0.97, 1.31] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002711 PGS000907
(PRS_MDD)
PSS001299|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Escitalopram takers OR: 0.96 [0.8, 1.14] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002712 PGS000907
(PRS_MDD)
PSS001304|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Venlafaxine takers OR: 1.22 [1.03, 1.45] Variance explained (Nagelkerke's R2*100): 0.51 sex, age at study enrollment, genetic PCs 1-20
PPM002713 PGS000907
(PRS_MDD)
PSS001295|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Amitriptyline takers OR: 1.06 [0.8, 1.4] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002715 PGS000907
(PRS_MDD)
PSS001297|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Desvenlafaxine takers OR: 1.0 [0.8, 1.24] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002716 PGS000907
(PRS_MDD)
PSS001296|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Citalopram takers OR: 0.95 [0.72, 1.27] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002717 PGS000907
(PRS_MDD)
PSS001300|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Fluoxetine takers OR: 1.3 [1.05, 1.6] Variance explained (Nagelkerke's R2*100): 0.77 sex, age at study enrollment, genetic PCs 1-20
PPM002718 PGS000907
(PRS_MDD)
PSS001298|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Duloxetine takers OR: 0.99 [0.82, 1.2] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002720 PGS000907
(PRS_MDD)
PSS001263|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Sertraline takers OR: 1.04 [0.98, 1.11] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002721 PGS000907
(PRS_MDD)
PSS001259|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Escitalopram takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002722 PGS000907
(PRS_MDD)
PSS001264|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Venlafaxine takers OR: 0.98 [0.91, 1.05] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002723 PGS000907
(PRS_MDD)
PSS001255|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Amitriptyline takers OR: 1.06 [0.95, 1.17] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002724 PGS000907
(PRS_MDD)
PSS001261|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Mirtazapine takers OR: 1.05 [0.94, 1.17] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002725 PGS000907
(PRS_MDD)
PSS001257|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Desvenlafaxine takers OR: 1.09 [0.99, 1.2] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002726 PGS000907
(PRS_MDD)
PSS001256|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Citalopram takers OR: 1.11 [1.0, 1.23] Variance explained (Nagelkerke's R2*100): 0.23 sex, age at study enrollment, genetic PCs 1-20
PPM002727 PGS000907
(PRS_MDD)
PSS001260|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Fluoxetine takers OR: 1.0 [0.92, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002728 PGS000907
(PRS_MDD)
PSS001258|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Duloxetine takers OR: 1.03 [0.93, 1.13] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002729 PGS000907
(PRS_MDD)
PSS001262|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Paroxetine takers OR: 0.98 [0.86, 1.1] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002730 PGS000907
(PRS_MDD)
PSS001403|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Sertraline takers OR: 0.99 [0.92, 1.07] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002731 PGS000907
(PRS_MDD)
PSS001399|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Escitalopram takers OR: 0.97 [0.89, 1.06] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002732 PGS000907
(PRS_MDD)
PSS001404|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Venlafaxine takers OR: 1.04 [0.96, 1.12] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002733 PGS000907
(PRS_MDD)
PSS001395|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Amitriptyline takers OR: 1.14 [0.96, 1.37] Variance explained (Nagelkerke's R2*100): 0.3 sex, age at study enrollment, genetic PCs 1-20
PPM002734 PGS000907
(PRS_MDD)
PSS001401|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Mirtazapine takers OR: 1.05 [0.9, 1.22] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002735 PGS000907
(PRS_MDD)
PSS001397|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Desvenlafaxine takers OR: 0.99 [0.9, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002736 PGS000907
(PRS_MDD)
PSS001396|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Citalopram takers OR: 1.14 [0.99, 1.3] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002737 PGS000907
(PRS_MDD)
PSS001400|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Fluoxetine takers OR: 1.04 [0.94, 1.16] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002738 PGS000907
(PRS_MDD)
PSS001398|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Duloxetine takers OR: 0.96 [0.86, 1.07] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002739 PGS000907
(PRS_MDD)
PSS001402|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Paroxetine takers OR: 1.1 [0.94, 1.28] Variance explained (Nagelkerke's R2*100): 0.17 sex, age at study enrollment, genetic PCs 1-20
PPM002741 PGS000907
(PRS_MDD)
PSS001309|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Escitalopram takers OR: 1.06 [0.98, 1.15] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002742 PGS000907
(PRS_MDD)
PSS001314|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Venlafaxine takers OR: 1.08 [1.0, 1.17] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002743 PGS000907
(PRS_MDD)
PSS001305|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Amitriptyline takers OR: 1.12 [0.95, 1.31] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002744 PGS000907
(PRS_MDD)
PSS001311|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Mirtazapine takers OR: 1.08 [0.93, 1.25] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002745 PGS000907
(PRS_MDD)
PSS001307|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Desvenlafaxine takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002746 PGS000907
(PRS_MDD)
PSS001306|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Citalopram takers OR: 1.11 [0.99, 1.25] Variance explained (Nagelkerke's R2*100): 0.24 sex, age at study enrollment, genetic PCs 1-20
PPM002747 PGS000907
(PRS_MDD)
PSS001310|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Fluoxetine takers OR: 1.06 [0.97, 1.16] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002748 PGS000907
(PRS_MDD)
PSS001308|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Duloxetine takers OR: 1.16 [1.04, 1.29] Variance explained (Nagelkerke's R2*100): 0.55 sex, age at study enrollment, genetic PCs 1-20
PPM002749 PGS000907
(PRS_MDD)
PSS001312|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Paroxetine takers OR: 1.1 [0.96, 1.27] Variance explained (Nagelkerke's R2*100): 0.21 sex, age at study enrollment, genetic PCs 1-20
PPM002750 PGS000907
(PRS_MDD)
PSS001423|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Sertraline takers OR: 1.21 [1.03, 1.43] Variance explained (Nagelkerke's R2*100): 0.44 sex, age at study enrollment, genetic PCs 1-20
PPM002751 PGS000907
(PRS_MDD)
PSS001419|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Escitalopram takers OR: 0.96 [0.78, 1.18] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002752 PGS000907
(PRS_MDD)
PSS001424|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Venlafaxine takers OR: 1.14 [0.96, 1.36] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002754 PGS000907
(PRS_MDD)
PSS001421|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Mirtazapine takers OR: 1.23 [0.88, 1.72] Variance explained (Nagelkerke's R2*100): 0.45 sex, age at study enrollment, genetic PCs 1-20
PPM002755 PGS000907
(PRS_MDD)
PSS001417|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Desvenlafaxine takers OR: 1.08 [0.86, 1.36] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002756 PGS000907
(PRS_MDD)
PSS001416|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Citalopram takers OR: 1.19 [0.87, 1.64] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002757 PGS000907
(PRS_MDD)
PSS001420|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Fluoxetine takers OR: 1.01 [0.8, 1.28] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002758 PGS000907
(PRS_MDD)
PSS001418|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Duloxetine takers OR: 1.09 [0.87, 1.35] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002759 PGS000907
(PRS_MDD)
PSS001422|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Paroxetine takers OR: 1.17 [0.86, 1.61] Variance explained (Nagelkerke's R2*100): 0.3 sex, age at study enrollment, genetic PCs 1-20
PPM002760 PGS000907
(PRS_MDD)
PSS001223|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Sertraline takers OR: 1.15 [1.03, 1.29] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002761 PGS000907
(PRS_MDD)
PSS001219|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Escitalopram takers OR: 1.16 [1.01, 1.33] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002762 PGS000907
(PRS_MDD)
PSS001224|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Venlafaxine takers OR: 1.19 [1.07, 1.34] Variance explained (Nagelkerke's R2*100): 0.54 sex, age at study enrollment, genetic PCs 1-20
PPM002763 PGS000907
(PRS_MDD)
PSS001215|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Amitriptyline takers OR: 1.16 [0.98, 1.37] Variance explained (Nagelkerke's R2*100): 0.38 sex, age at study enrollment, genetic PCs 1-20
PPM002764 PGS000907
(PRS_MDD)
PSS001221|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Mirtazapine takers OR: 1.08 [0.89, 1.29] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002765 PGS000907
(PRS_MDD)
PSS001217|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Desvenlafaxine takers OR: 1.03 [0.89, 1.2] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002767 PGS000907
(PRS_MDD)
PSS001220|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Fluoxetine takers OR: 1.09 [0.94, 1.27] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002768 PGS000907
(PRS_MDD)
PSS001218|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Duloxetine takers OR: 1.02 [0.89, 1.18] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002769 PGS000907
(PRS_MDD)
PSS001222|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Paroxetine takers OR: 1.09 [0.9, 1.31] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002771 PGS000907
(PRS_MDD)
PSS001229|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Escitalopram takers OR: 1.01 [0.89, 1.16] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002772 PGS000907
(PRS_MDD)
PSS001234|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Venlafaxine takers OR: 1.13 [0.97, 1.32] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002773 PGS000907
(PRS_MDD)
PSS001225|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Amitriptyline takers OR: 1.02 [0.73, 1.42] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002774 PGS000907
(PRS_MDD)
PSS001231|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Mirtazapine takers OR: 1.13 [0.89, 1.42] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002775 PGS000907
(PRS_MDD)
PSS001227|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Desvenlafaxine takers OR: 1.01 [0.84, 1.21] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002776 PGS000907
(PRS_MDD)
PSS001226|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Citalopram takers OR: 0.95 [0.76, 1.19] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002777 PGS000907
(PRS_MDD)
PSS001230|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Fluoxetine takers OR: 0.99 [0.84, 1.17] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002778 PGS000907
(PRS_MDD)
PSS001228|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Duloxetine takers OR: 1.08 [0.9, 1.3] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002779 PGS000907
(PRS_MDD)
PSS001232|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Paroxetine takers OR: 1.47 [1.13, 1.91] Variance explained (Nagelkerke's R2*100): 1.92 sex, age at study enrollment, genetic PCs 1-20
PPM002780 PGS000907
(PRS_MDD)
PSS001253|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Sertraline takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002782 PGS000907
(PRS_MDD)
PSS001254|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Venlafaxine takers OR: 1.0 [0.91, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002783 PGS000907
(PRS_MDD)
PSS001245|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Amitriptyline takers OR: 0.99 [0.89, 1.11] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002784 PGS000907
(PRS_MDD)
PSS001251|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Mirtazapine takers OR: 1.06 [0.96, 1.18] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002785 PGS000907
(PRS_MDD)
PSS001247|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Desvenlafaxine takers OR: 0.99 [0.88, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002786 PGS000907
(PRS_MDD)
PSS001246|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Citalopram takers OR: 1.05 [0.93, 1.18] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002787 PGS000907
(PRS_MDD)
PSS001250|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Fluoxetine takers OR: 1.04 [0.94, 1.14] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002788 PGS000907
(PRS_MDD)
PSS001248|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Duloxetine takers OR: 0.96 [0.86, 1.08] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002789 PGS000907
(PRS_MDD)
PSS001252|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Paroxetine takers OR: 0.97 [0.83, 1.12] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002790 PGS000907
(PRS_MDD)
PSS001413|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Sertraline takers OR: 1.04 [0.97, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002791 PGS000907
(PRS_MDD)
PSS001409|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Escitalopram takers OR: 1.02 [0.94, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002792 PGS000907
(PRS_MDD)
PSS001414|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Venlafaxine takers OR: 1.02 [0.94, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002793 PGS000907
(PRS_MDD)
PSS001405|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Amitriptyline takers OR: 1.05 [0.88, 1.26] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002794 PGS000907
(PRS_MDD)
PSS001411|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Mirtazapine takers OR: 1.13 [0.97, 1.32] Variance explained (Nagelkerke's R2*100): 0.27 sex, age at study enrollment, genetic PCs 1-20
PPM002795 PGS000907
(PRS_MDD)
PSS001407|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Desvenlafaxine takers OR: 1.05 [0.95, 1.16] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002796 PGS000907
(PRS_MDD)
PSS001406|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Citalopram takers OR: 1.0 [0.89, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002797 PGS000907
(PRS_MDD)
PSS001410|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Fluoxetine takers OR: 1.05 [0.96, 1.15] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002798 PGS000907
(PRS_MDD)
PSS001408|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Duloxetine takers OR: 0.97 [0.87, 1.09] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002800 PGS000907
(PRS_MDD)
PSS001203|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Sertraline takers OR: 1.13 [1.04, 1.22] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002801 PGS000907
(PRS_MDD)
PSS001199|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Escitalopram takers OR: 1.01 [0.91, 1.11] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002802 PGS000907
(PRS_MDD)
PSS001204|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Venlafaxine takers OR: 1.14 [1.04, 1.26] Variance explained (Nagelkerke's R2*100): 0.36 sex, age at study enrollment, genetic PCs 1-20
PPM002803 PGS000907
(PRS_MDD)
PSS001195|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Amitriptyline takers OR: 1.05 [0.87, 1.27] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002804 PGS000907
(PRS_MDD)
PSS001201|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Mirtazapine takers OR: 1.2 [1.03, 1.39] Variance explained (Nagelkerke's R2*100): 0.59 sex, age at study enrollment, genetic PCs 1-20
PPM002805 PGS000907
(PRS_MDD)
PSS001197|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Desvenlafaxine takers OR: 1.04 [0.92, 1.17] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002806 PGS000907
(PRS_MDD)
PSS001196|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Citalopram takers OR: 0.97 [0.85, 1.12] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002807 PGS000907
(PRS_MDD)
PSS001200|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Fluoxetine takers OR: 1.05 [0.96, 1.16] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002808 PGS000907
(PRS_MDD)
PSS001198|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Duloxetine takers OR: 1.0 [0.87, 1.14] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002809 PGS000907
(PRS_MDD)
PSS001202|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Paroxetine takers OR: 1.1 [0.94, 1.29] Variance explained (Nagelkerke's R2*100): 0.19 sex, age at study enrollment, genetic PCs 1-20
PPM002810 PGS000907
(PRS_MDD)
PSS001193|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Sertraline takers OR: 1.04 [0.96, 1.13] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002811 PGS000907
(PRS_MDD)
PSS001189|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Escitalopram takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002812 PGS000907
(PRS_MDD)
PSS001194|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Venlafaxine takers OR: 1.06 [0.97, 1.17] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002813 PGS000907
(PRS_MDD)
PSS001185|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Amitriptyline takers OR: 1.02 [0.85, 1.23] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002814 PGS000907
(PRS_MDD)
PSS001191|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Mirtazapine takers OR: 1.25 [1.08, 1.46] Variance explained (Nagelkerke's R2*100): 0.93 sex, age at study enrollment, genetic PCs 1-20
PPM002816 PGS000907
(PRS_MDD)
PSS001186|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Citalopram takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002817 PGS000907
(PRS_MDD)
PSS001190|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Fluoxetine takers OR: 1.06 [0.96, 1.18] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002818 PGS000907
(PRS_MDD)
PSS001188|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Duloxetine takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002819 PGS000907
(PRS_MDD)
PSS001192|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Paroxetine takers OR: 1.19 [1.02, 1.38] Variance explained (Nagelkerke's R2*100): 0.6 sex, age at study enrollment, genetic PCs 1-20
PPM002820 PGS000907
(PRS_MDD)
PSS001273|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Sertraline takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002821 PGS000907
(PRS_MDD)
PSS001269|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Escitalopram takers OR: 0.96 [0.88, 1.05] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002822 PGS000907
(PRS_MDD)
PSS001274|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Venlafaxine takers OR: 1.06 [0.97, 1.16] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002823 PGS000907
(PRS_MDD)
PSS001265|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Amitriptyline takers OR: 1.12 [0.97, 1.28] Variance explained (Nagelkerke's R2*100): 0.25 sex, age at study enrollment, genetic PCs 1-20
PPM002824 PGS000907
(PRS_MDD)
PSS001271|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Mirtazapine takers OR: 1.06 [0.94, 1.2] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002826 PGS000907
(PRS_MDD)
PSS001266|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Citalopram takers OR: 0.98 [0.86, 1.11] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002827 PGS000907
(PRS_MDD)
PSS001270|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Fluoxetine takers OR: 1.02 [0.92, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002829 PGS000907
(PRS_MDD)
PSS001272|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Paroxetine takers OR: 0.96 [0.82, 1.11] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002831 PGS000907
(PRS_MDD)
PSS001429|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Escitalopram takers OR: 1.04 [0.97, 1.11] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002832 PGS000907
(PRS_MDD)
PSS001434|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Venlafaxine takers OR: 1.03 [0.96, 1.11] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002833 PGS000907
(PRS_MDD)
PSS001425|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Amitriptyline takers OR: 1.06 [0.95, 1.19] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002834 PGS000907
(PRS_MDD)
PSS001431|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Mirtazapine takers OR: 1.02 [0.93, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002835 PGS000907
(PRS_MDD)
PSS001427|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Desvenlafaxine takers OR: 1.11 [1.02, 1.22] Variance explained (Nagelkerke's R2*100): 0.33 sex, age at study enrollment, genetic PCs 1-20
PPM002836 PGS000907
(PRS_MDD)
PSS001426|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Citalopram takers OR: 1.14 [1.03, 1.25] Variance explained (Nagelkerke's R2*100): 0.4 sex, age at study enrollment, genetic PCs 1-20
PPM002837 PGS000907
(PRS_MDD)
PSS001430|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Fluoxetine takers OR: 1.04 [0.96, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002838 PGS000907
(PRS_MDD)
PSS001428|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Duloxetine takers OR: 1.0 [0.91, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002839 PGS000907
(PRS_MDD)
PSS001432|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Paroxetine takers OR: 1.11 [0.99, 1.24] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002840 PGS000907
(PRS_MDD)
PSS001443|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Sertraline takers OR: 0.9 [0.75, 1.07] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002841 PGS000907
(PRS_MDD)
PSS001439|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Escitalopram takers OR: 1.07 [0.88, 1.32] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002842 PGS000907
(PRS_MDD)
PSS001444|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Venlafaxine takers OR: 1.05 [0.84, 1.3] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002844 PGS000907
(PRS_MDD)
PSS001441|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Mirtazapine takers OR: 1.21 [0.85, 1.71] Variance explained (Nagelkerke's R2*100): 0.37 sex, age at study enrollment, genetic PCs 1-20
PPM002845 PGS000907
(PRS_MDD)
PSS001437|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Desvenlafaxine takers OR: 0.95 [0.74, 1.22] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002846 PGS000907
(PRS_MDD)
PSS001436|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Citalopram takers OR: 0.87 [0.61, 1.23] Variance explained (Nagelkerke's R2*100): 0.19 sex, age at study enrollment, genetic PCs 1-20
PPM002847 PGS000907
(PRS_MDD)
PSS001440|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Fluoxetine takers OR: 1.16 [0.96, 1.39] Variance explained (Nagelkerke's R2*100): 0.26 sex, age at study enrollment, genetic PCs 1-20
PPM002848 PGS000907
(PRS_MDD)
PSS001438|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Duloxetine takers OR: 0.96 [0.75, 1.23] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002849 PGS000907
(PRS_MDD)
PSS001442|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Paroxetine takers OR: 1.36 [0.88, 2.1] Variance explained (Nagelkerke's R2*100): 0.99 sex, age at study enrollment, genetic PCs 1-20
PPM002852 PGS000907
(PRS_MDD)
PSS001344|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Venlafaxine takers OR: 1.0 [0.74, 1.36] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002853 PGS000907
(PRS_MDD)
PSS001335|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Amitriptyline takers OR: 1.22 [0.73, 2.04] Variance explained (Nagelkerke's R2*100): 0.42 sex, age at study enrollment, genetic PCs 1-20
PPM002854 PGS000907
(PRS_MDD)
PSS001341|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Mirtazapine takers OR: 1.0 [0.65, 1.52] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002855 PGS000907
(PRS_MDD)
PSS001337|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Desvenlafaxine takers OR: 1.58 [1.13, 2.23] Variance explained (Nagelkerke's R2*100): 2.19 sex, age at study enrollment, genetic PCs 1-20
PPM002856 PGS000907
(PRS_MDD)
PSS001336|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Citalopram takers OR: 1.1 [0.7, 1.74] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002857 PGS000907
(PRS_MDD)
PSS001340|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Fluoxetine takers OR: 1.34 [0.91, 1.97] Variance explained (Nagelkerke's R2*100): 0.75 sex, age at study enrollment, genetic PCs 1-20
PPM002858 PGS000907
(PRS_MDD)
PSS001338|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Duloxetine takers OR: 1.13 [0.75, 1.7] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002859 PGS000907
(PRS_MDD)
PSS001342|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Paroxetine takers OR: 1.16 [0.69, 1.95] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002860 PGS000907
(PRS_MDD)
PSS001363|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Sertraline takers OR: 1.0 [0.79, 1.28] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002861 PGS000907
(PRS_MDD)
PSS001359|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Escitalopram takers OR: 0.91 [0.69, 1.19] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002862 PGS000907
(PRS_MDD)
PSS001364|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Venlafaxine takers OR: 1.06 [0.8, 1.42] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002863 PGS000907
(PRS_MDD)
PSS001355|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Amitriptyline takers OR: 0.59 [0.36, 0.98] Variance explained (Nagelkerke's R2*100): 2.43 sex, age at study enrollment, genetic PCs 1-20
PPM002864 PGS000907
(PRS_MDD)
PSS001361|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Mirtazapine takers OR: 0.85 [0.55, 1.3] Variance explained (Nagelkerke's R2*100): 0.25 sex, age at study enrollment, genetic PCs 1-20
PPM002865 PGS000907
(PRS_MDD)
PSS001357|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Desvenlafaxine takers OR: 0.8 [0.59, 1.07] Variance explained (Nagelkerke's R2*100): 0.58 sex, age at study enrollment, genetic PCs 1-20
PPM002868 PGS000907
(PRS_MDD)
PSS001358|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Duloxetine takers OR: 0.99 [0.71, 1.38] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002869 PGS000907
(PRS_MDD)
PSS001362|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Paroxetine takers OR: 0.9 [0.53, 1.52] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002870 PGS000907
(PRS_MDD)
PSS001353|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Sertraline takers OR: 1.0 [0.95, 1.06] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002871 PGS000907
(PRS_MDD)
PSS001349|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Escitalopram takers OR: 0.99 [0.93, 1.06] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002872 PGS000907
(PRS_MDD)
PSS001354|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Venlafaxine takers OR: 1.05 [0.99, 1.13] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002873 PGS000907
(PRS_MDD)
PSS001345|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Amitriptyline takers OR: 1.08 [0.96, 1.22] Variance explained (Nagelkerke's R2*100): 0.16 sex, age at study enrollment, genetic PCs 1-20
PPM002878 PGS000907
(PRS_MDD)
PSS001348|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Duloxetine takers OR: 0.99 [0.91, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002879 PGS000907
(PRS_MDD)
PSS001352|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Paroxetine takers OR: 1.0 [0.9, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002883 PGS000907
(PRS_MDD)
PSS001205|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Amitriptyline takers OR: 1.08 [0.86, 1.36] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002884 PGS000907
(PRS_MDD)
PSS001211|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Mirtazapine takers OR: 1.05 [0.84, 1.31] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002885 PGS000907
(PRS_MDD)
PSS001207|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Desvenlafaxine takers OR: 1.13 [0.94, 1.37] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002886 PGS000907
(PRS_MDD)
PSS001206|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Citalopram takers OR: 1.39 [1.08, 1.79] Variance explained (Nagelkerke's R2*100): 1.2 sex, age at study enrollment, genetic PCs 1-20
PPM002887 PGS000907
(PRS_MDD)
PSS001210|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Fluoxetine takers OR: 1.03 [0.85, 1.24] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002888 PGS000907
(PRS_MDD)
PSS001208|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Duloxetine takers OR: 1.04 [0.87, 1.26] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002889 PGS000907
(PRS_MDD)
PSS001212|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Paroxetine takers OR: 1.32 [1.0, 1.75] Variance explained (Nagelkerke's R2*100): 0.99 sex, age at study enrollment, genetic PCs 1-20
PPM002890 PGS000907
(PRS_MDD)
PSS001393|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Sertraline takers OR: 1.24 [1.14, 1.34] Variance explained (Nagelkerke's R2*100): 0.9 sex, age at study enrollment, genetic PCs 1-20
PPM002894 PGS000907
(PRS_MDD)
PSS001391|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Mirtazapine takers OR: 1.09 [0.94, 1.25] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002895 PGS000907
(PRS_MDD)
PSS001387|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Desvenlafaxine takers OR: 1.06 [0.94, 1.2] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002896 PGS000907
(PRS_MDD)
PSS001386|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Citalopram takers OR: 1.06 [0.92, 1.22] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002897 PGS000907
(PRS_MDD)
PSS001390|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Fluoxetine takers OR: 1.12 [1.02, 1.23] Variance explained (Nagelkerke's R2*100): 0.27 sex, age at study enrollment, genetic PCs 1-20
PPM002898 PGS000907
(PRS_MDD)
PSS001388|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Duloxetine takers OR: 0.98 [0.86, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002899 PGS000907
(PRS_MDD)
PSS001392|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Paroxetine takers OR: 1.22 [1.05, 1.42] Variance explained (Nagelkerke's R2*100): 0.8 sex, age at study enrollment, genetic PCs 1-20
PPM002900 PGS000907
(PRS_MDD)
PSS001383|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Sertraline takers OR: 1.15 [1.01, 1.31] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002901 PGS000907
(PRS_MDD)
PSS001379|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Escitalopram takers OR: 1.06 [0.9, 1.24] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002902 PGS000907
(PRS_MDD)
PSS001384|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Venlafaxine takers OR: 1.36 [1.18, 1.58] Variance explained (Nagelkerke's R2*100): 1.35 sex, age at study enrollment, genetic PCs 1-20
PPM002903 PGS000907
(PRS_MDD)
PSS001375|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Amitriptyline takers OR: 0.97 [0.75, 1.24] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002904 PGS000907
(PRS_MDD)
PSS001381|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Mirtazapine takers OR: 1.11 [0.88, 1.4] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002905 PGS000907
(PRS_MDD)
PSS001377|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Desvenlafaxine takers OR: 0.97 [0.78, 1.21] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002906 PGS000907
(PRS_MDD)
PSS001376|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Citalopram takers OR: 0.96 [0.76, 1.21] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002907 PGS000907
(PRS_MDD)
PSS001380|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Fluoxetine takers OR: 1.09 [0.95, 1.26] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002908 PGS000907
(PRS_MDD)
PSS001378|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Duloxetine takers OR: 1.11 [0.89, 1.38] Variance explained (Nagelkerke's R2*100): 0.15 sex, age at study enrollment, genetic PCs 1-20
PPM002909 PGS000907
(PRS_MDD)
PSS001382|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Paroxetine takers OR: 1.22 [0.95, 1.55] Variance explained (Nagelkerke's R2*100): 0.54 sex, age at study enrollment, genetic PCs 1-20
PPM002910 PGS000907
(PRS_MDD)
PSS001333|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Sertraline takers OR: 0.99 [0.91, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002911 PGS000907
(PRS_MDD)
PSS001329|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Escitalopram takers OR: 0.96 [0.86, 1.07] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002912 PGS000907
(PRS_MDD)
PSS001334|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Venlafaxine takers OR: 1.14 [1.03, 1.27] Variance explained (Nagelkerke's R2*100): 0.31 sex, age at study enrollment, genetic PCs 1-20
PPM002913 PGS000907
(PRS_MDD)
PSS001325|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Amitriptyline takers OR: 1.07 [0.88, 1.29] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002914 PGS000907
(PRS_MDD)
PSS001331|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Mirtazapine takers OR: 1.03 [0.87, 1.2] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002915 PGS000907
(PRS_MDD)
PSS001327|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Desvenlafaxine takers OR: 1.02 [0.88, 1.18] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002916 PGS000907
(PRS_MDD)
PSS001326|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Citalopram takers OR: 0.95 [0.82, 1.1] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002917 PGS000907
(PRS_MDD)
PSS001330|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Fluoxetine takers OR: 1.05 [0.93, 1.18] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002918 PGS000907
(PRS_MDD)
PSS001328|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Duloxetine takers OR: 1.04 [0.89, 1.2] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002919 PGS000907
(PRS_MDD)
PSS001332|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Paroxetine takers OR: 0.97 [0.81, 1.16] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002920 PGS000907
(PRS_MDD)
PSS001323|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Sertraline takers OR: 1.04 [0.89, 1.21] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002921 PGS000907
(PRS_MDD)
PSS001319|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Escitalopram takers OR: 1.04 [0.89, 1.22] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002922 PGS000907
(PRS_MDD)
PSS001324|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Venlafaxine takers OR: 0.94 [0.79, 1.12] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002923 PGS000907
(PRS_MDD)
PSS001315|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Amitriptyline takers OR: 1.03 [0.84, 1.25] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002924 PGS000907
(PRS_MDD)
PSS001321|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Mirtazapine takers OR: 1.05 [0.83, 1.33] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002925 PGS000907
(PRS_MDD)
PSS001317|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Desvenlafaxine takers OR: 0.82 [0.68, 0.98] Variance explained (Nagelkerke's R2*100): 0.6 sex, age at study enrollment, genetic PCs 1-20
PPM002930 PGS000910
(PRS_BMI)
PSS001433|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Sertraline takers OR: 1.27 [1.19, 1.35] Variance explained (Nagelkerke's R2*100): 1.57 sex, age at study enrollment, genetic PCs 1-20
PPM002931 PGS000910
(PRS_BMI)
PSS001429|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Escitalopram takers OR: 1.22 [1.14, 1.31] Variance explained (Nagelkerke's R2*100): 1.17 sex, age at study enrollment, genetic PCs 1-20
PPM002932 PGS000910
(PRS_BMI)
PSS001434|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Venlafaxine takers OR: 1.23 [1.14, 1.32] Variance explained (Nagelkerke's R2*100): 1.28 sex, age at study enrollment, genetic PCs 1-20
PPM002933 PGS000910
(PRS_BMI)
PSS001425|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Amitriptyline takers OR: 1.27 [1.13, 1.42] Variance explained (Nagelkerke's R2*100): 1.74 sex, age at study enrollment, genetic PCs 1-20
PPM002935 PGS000910
(PRS_BMI)
PSS001427|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Desvenlafaxine takers OR: 1.24 [1.13, 1.36] Variance explained (Nagelkerke's R2*100): 1.36 sex, age at study enrollment, genetic PCs 1-20
PPM002936 PGS000910
(PRS_BMI)
PSS001426|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Citalopram takers OR: 1.39 [1.26, 1.53] Variance explained (Nagelkerke's R2*100): 2.83 sex, age at study enrollment, genetic PCs 1-20
PPM002937 PGS000910
(PRS_BMI)
PSS001430|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Fluoxetine takers OR: 1.3 [1.2, 1.4] Variance explained (Nagelkerke's R2*100): 1.87 sex, age at study enrollment, genetic PCs 1-20
PPM002938 PGS000910
(PRS_BMI)
PSS001428|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Duloxetine takers OR: 1.21 [1.1, 1.34] Variance explained (Nagelkerke's R2*100): 1.26 sex, age at study enrollment, genetic PCs 1-20
PPM002940 PGS000909
(PRS_Headaches)
PSS001283|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Sertraline takers OR: 1.16 [1.08, 1.25] Variance explained (Nagelkerke's R2*100): 0.49 sex, age at study enrollment, genetic PCs 1-20
PPM002941 PGS000909
(PRS_Headaches)
PSS001279|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Escitalopram takers OR: 1.06 [0.97, 1.16] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002942 PGS000909
(PRS_Headaches)
PSS001284|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Venlafaxine takers OR: 1.11 [1.01, 1.21] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002943 PGS000909
(PRS_Headaches)
PSS001275|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Amitriptyline takers OR: 1.09 [0.93, 1.28] Variance explained (Nagelkerke's R2*100): 0.15 sex, age at study enrollment, genetic PCs 1-20
PPM002944 PGS000909
(PRS_Headaches)
PSS001281|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Mirtazapine takers OR: 1.04 [0.9, 1.2] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002945 PGS000909
(PRS_Headaches)
PSS001277|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Desvenlafaxine takers OR: 1.08 [0.98, 1.2] Variance explained (Nagelkerke's R2*100): 0.16 sex, age at study enrollment, genetic PCs 1-20
PPM002946 PGS000909
(PRS_Headaches)
PSS001276|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Citalopram takers OR: 1.11 [0.98, 1.26] Variance explained (Nagelkerke's R2*100): 0.23 sex, age at study enrollment, genetic PCs 1-20
PPM002947 PGS000909
(PRS_Headaches)
PSS001280|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Fluoxetine takers OR: 1.02 [0.93, 1.12] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002948 PGS000909
(PRS_Headaches)
PSS001278|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Duloxetine takers OR: 1.03 [0.92, 1.15] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002949 PGS000909
(PRS_Headaches)
PSS001282|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Paroxetine takers OR: 1.16 [1.0, 1.35] Variance explained (Nagelkerke's R2*100): 0.46 sex, age at study enrollment, genetic PCs 1-20
PPM002950 PGS000908
(PRS_Insomnia)
PSS001293|
European Ancestry|
5,713 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Sertraline takers OR: 1.06 [0.99, 1.14] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002951 PGS000908
(PRS_Insomnia)
PSS001289|
European Ancestry|
4,362 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Escitalopram takers OR: 1.12 [1.03, 1.21] Variance explained (Nagelkerke's R2*100): 0.27 sex, age at study enrollment, genetic PCs 1-20
PPM002952 PGS000908
(PRS_Insomnia)
PSS001294|
European Ancestry|
3,964 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Venlafaxine takers OR: 1.03 [0.95, 1.11] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002953 PGS000908
(PRS_Insomnia)
PSS001285|
European Ancestry|
1,655 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Amitriptyline takers OR: 1.28 [1.07, 1.52] Variance explained (Nagelkerke's R2*100): 1.03 sex, age at study enrollment, genetic PCs 1-20
PPM002954 PGS000908
(PRS_Insomnia)
PSS001291|
European Ancestry|
1,986 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Mirtazapine takers OR: 1.03 [0.88, 1.2] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002955 PGS000908
(PRS_Insomnia)
PSS001287|
European Ancestry|
2,523 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Desvenlafaxine takers OR: 1.13 [1.03, 1.25] Variance explained (Nagelkerke's R2*100): 0.38 sex, age at study enrollment, genetic PCs 1-20
PPM002956 PGS000908
(PRS_Insomnia)
PSS001286|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Citalopram takers OR: 1.08 [0.96, 1.21] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002957 PGS000908
(PRS_Insomnia)
PSS001290|
European Ancestry|
3,665 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Fluoxetine takers OR: 1.03 [0.94, 1.13] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002958 PGS000908
(PRS_Insomnia)
PSS001288|
European Ancestry|
1,994 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Duloxetine takers OR: 1.14 [1.02, 1.28] Variance explained (Nagelkerke's R2*100): 0.4 sex, age at study enrollment, genetic PCs 1-20
PPM002680 PGS000907
(PRS_MDD)
PSS001283|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Sertraline takers OR: 1.03 [0.95, 1.11] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002683 PGS000907
(PRS_MDD)
PSS001275|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Amitriptyline takers OR: 0.96 [0.81, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002706 PGS000907
(PRS_MDD)
PSS001366|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Citalopram takers OR: 1.16 [0.98, 1.38] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002714 PGS000907
(PRS_MDD)
PSS001301|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Mirtazapine takers OR: 1.13 [0.9, 1.43] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002719 PGS000907
(PRS_MDD)
PSS001302|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Paroxetine takers OR: 1.18 [0.87, 1.61] Variance explained (Nagelkerke's R2*100): 0.34 sex, age at study enrollment, genetic PCs 1-20
PPM002740 PGS000907
(PRS_MDD)
PSS001313|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Sertraline takers OR: 1.08 [1.01, 1.15] Variance explained (Nagelkerke's R2*100): 0.13 sex, age at study enrollment, genetic PCs 1-20
PPM002753 PGS000907
(PRS_MDD)
PSS001415|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Amitriptyline takers OR: 0.93 [0.65, 1.33] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002766 PGS000907
(PRS_MDD)
PSS001216|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Citalopram takers OR: 1.02 [0.85, 1.22] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002770 PGS000907
(PRS_MDD)
PSS001233|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Sertraline takers OR: 1.05 [0.94, 1.16] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002781 PGS000907
(PRS_MDD)
PSS001249|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Escitalopram takers OR: 0.96 [0.89, 1.05] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002799 PGS000907
(PRS_MDD)
PSS001412|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Paroxetine takers OR: 1.06 [0.92, 1.22] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002815 PGS000907
(PRS_MDD)
PSS001187|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Desvenlafaxine takers OR: 1.07 [0.94, 1.21] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002825 PGS000907
(PRS_MDD)
PSS001267|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Desvenlafaxine takers OR: 1.02 [0.91, 1.15] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002828 PGS000907
(PRS_MDD)
PSS001268|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Duloxetine takers OR: 0.93 [0.83, 1.04] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002830 PGS000907
(PRS_MDD)
PSS001433|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Sertraline takers OR: 1.02 [0.96, 1.08] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002843 PGS000907
(PRS_MDD)
PSS001435|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Amitriptyline takers OR: 1.09 [0.67, 1.78] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002850 PGS000907
(PRS_MDD)
PSS001343|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Sertraline takers OR: 1.04 [0.8, 1.36] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002851 PGS000907
(PRS_MDD)
PSS001339|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Escitalopram takers OR: 1.09 [0.79, 1.5] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002866 PGS000907
(PRS_MDD)
PSS001356|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Citalopram takers OR: 1.05 [0.73, 1.51] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002867 PGS000907
(PRS_MDD)
PSS001360|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Fluoxetine takers OR: 1.03 [0.76, 1.4] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002874 PGS000907
(PRS_MDD)
PSS001351|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Mirtazapine takers OR: 0.99 [0.9, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002875 PGS000907
(PRS_MDD)
PSS001347|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Desvenlafaxine takers OR: 1.11 [1.02, 1.21] Variance explained (Nagelkerke's R2*100): 0.34 sex, age at study enrollment, genetic PCs 1-20
PPM002876 PGS000907
(PRS_MDD)
PSS001346|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Citalopram takers OR: 1.1 [1.01, 1.2] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002877 PGS000907
(PRS_MDD)
PSS001350|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Fluoxetine takers OR: 1.05 [0.98, 1.12] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002880 PGS000907
(PRS_MDD)
PSS001213|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Sertraline takers OR: 0.96 [0.83, 1.11] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002881 PGS000907
(PRS_MDD)
PSS001209|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Escitalopram takers OR: 1.03 [0.87, 1.22] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002882 PGS000907
(PRS_MDD)
PSS001214|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Venlafaxine takers OR: 0.97 [0.84, 1.12] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002891 PGS000907
(PRS_MDD)
PSS001389|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Escitalopram takers OR: 1.09 [0.99, 1.2] Variance explained (Nagelkerke's R2*100): 0.15 sex, age at study enrollment, genetic PCs 1-20
PPM002892 PGS000907
(PRS_MDD)
PSS001394|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Venlafaxine takers OR: 1.19 [1.09, 1.31] Variance explained (Nagelkerke's R2*100): 0.63 sex, age at study enrollment, genetic PCs 1-20
PPM002893 PGS000907
(PRS_MDD)
PSS001385|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Amitriptyline takers OR: 0.94 [0.8, 1.11] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002926 PGS000907
(PRS_MDD)
PSS001316|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Citalopram takers OR: 1.08 [0.92, 1.28] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002927 PGS000907
(PRS_MDD)
PSS001320|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Fluoxetine takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002928 PGS000907
(PRS_MDD)
PSS001318|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Duloxetine takers OR: 0.91 [0.74, 1.13] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002929 PGS000907
(PRS_MDD)
PSS001322|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Paroxetine takers OR: 0.97 [0.77, 1.22] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002934 PGS000910
(PRS_BMI)
PSS001431|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Mirtazapine takers OR: 1.21 [1.1, 1.33] Variance explained (Nagelkerke's R2*100): 1.23 sex, age at study enrollment, genetic PCs 1-20
PPM002939 PGS000910
(PRS_BMI)
PSS001432|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Paroxetine takers OR: 1.19 [1.06, 1.33] Variance explained (Nagelkerke's R2*100): 0.84 sex, age at study enrollment, genetic PCs 1-20
PPM002959 PGS000908
(PRS_Insomnia)
PSS001292|
European Ancestry|
1,577 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Insomnia in Paroxetine takers OR: 1.16 [1.01, 1.33] Variance explained (Nagelkerke's R2*100): 0.47 sex, age at study enrollment, genetic PCs 1-20

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001185
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001186
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001187
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001188
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001189
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001190
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001191
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001192
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001193
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001194
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001195
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001196
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001197
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001198
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001199
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001200
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001201
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001202
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001203
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001204
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001205
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001206
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001207
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001208
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001209
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001210
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001211
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001212
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001213
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001214
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001215
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001216
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001217
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001218
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001219
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001220
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001221
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001222
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001223
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001224
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001225
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001226
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001227
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001228
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001229
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001230
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001231
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001232
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001233
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001234
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001235
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001236
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001237
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001238
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001239
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001240
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001241
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001242
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001243
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001244
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001245
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001246
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001247
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001248
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001249
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001250
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001251
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001252
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001253
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001254
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001255
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001256
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001257
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001258
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001259
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001260
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001261
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001262
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001263
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001264
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001265
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001266
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001267
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001268
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001269
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001270
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001271
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001272
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001273
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001274
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001275
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001276
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001277
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001278
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001279
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001280
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001281
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001282
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001283
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001284
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001285
[
  • 140 cases
  • , 1,515 controls
]
European AGDS
PSS001286
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001287
[
  • 488 cases
  • , 2,035 controls
]
European AGDS
PSS001288
[
  • 382 cases
  • , 1,612 controls
]
European AGDS
PSS001289
[
  • 712 cases
  • , 3,650 controls
]
European AGDS
PSS001290
[
  • 582 cases
  • , 3,083 controls
]
European AGDS
PSS001291
[
  • 186 cases
  • , 1,800 controls
]
European AGDS
PSS001292
[
  • 235 cases
  • , 1,342 controls
]
European AGDS
PSS001293
[
  • 1,018 cases
  • , 4,695 controls
]
European AGDS
PSS001294
[
  • 793 cases
  • , 3,171 controls
]
European AGDS
PSS001295
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001296
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001297
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001298
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001299
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001300
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001301
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001302
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001303
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001304
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001305
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001306
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001307
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001308
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001309
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001310
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001311
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001312
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001313
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001314
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001315
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001316
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001317
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001318
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001319
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001320
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001321
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001322
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001323
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001324
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001325
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001326
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001327
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001328
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001329
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001330
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001331
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001332
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001333
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001334
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001335
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001336
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001337
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001338
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001339
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001340
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001341
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001342
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001343
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001344
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001345
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001346
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001347
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001348
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001349
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001350
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001351
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001352
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001353
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001354
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001355
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001356
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001357
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001358
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001359
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001360
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001361
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001362
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001363
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001364
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001365
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001366
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001367
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001368
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001369
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001370
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001371
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001372
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001373
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001374
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001375
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001376
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001377
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001378
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001379
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001380
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001381
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001382
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001383
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001384
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001385
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001386
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001387
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001388
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001389
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001390
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001391
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001392
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001393
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001394
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001395
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001396
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001397
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001398
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001399
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001400
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001401
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001402
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001403
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001404
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001405
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001406
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001407
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001408
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001409
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001410
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001411
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001412
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001413
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001414
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001415
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001416
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001417
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001418
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001419
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001420
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001421
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001422
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001423
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001424
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001425
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001426
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001427
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001428
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001429
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001430
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001431
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001432
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001433
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001434
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001435
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001436
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001437
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001438
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001439
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001440
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001441
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001442
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001443
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001444
[
  • 794 cases
  • , 3,173 controls
]
European AGDS